BioCentury
ARTICLE | Clinical News

Cerecor reports Ph II depression data for CERC-501

May 5, 2017 1:39 AM UTC

Cerecor Inc. (NASDAQ:CERC) reported top-line data from a Phase II trial in 8 evaluable patients with treatment-resistant depression on stable antidepressant therapy showing that once-daily CERC-501 led to a "clinically meaningful" 2-point improvement compared to placebo on the primary endpoint of the change from baseline on the 6-item Hamilton Rating Scale for Depression (HAM-D-6) at 72 hours.

Cerecor also said the kappa opioid receptor (KOR; OPRK1) antagonist led to "clinically meaningful" improvements compared to placebo on the secondary endpoints of the number of responders with a ≥50% reduction in HAM-D-6 at 72 hours, MADRS, Perceived Stress Scale (3.5 point improvement vs. 0.5 point worsening), CGI-I, CGI-S, Symptoms of Depression Questionnaire and Positive Affect Scale. CERC-501 was generally well tolerated with no serious adverse events reported...